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Barriers to management of HCV in injection drug users are related to patients, health providers, and facilities. In a primary care
drug user’s addiction centre we studied access to HCV standard of care before and after using an onsite total care concept provided
by a multidisciplinary team and noninvasive liver ﬁbrosis evaluation. A total of 586 patients were seen between 2002 and 2004.
The majority, 417 patients, were HCV positive and of these patients 337 were tested positive for HCV RNA. In 2002, patients were
sent to the hospital. with the Starting of 2003, patients were oﬀered standard of care HCV management in the center by a team of
general practitioners, a consultant hepatologist, psychiatrists, nurses, and a health counsellor. Liver ﬁbrosis was assessed by a non
invasive method. In 2002, 6 patients had liver ﬁbrosis assessment at hospital facilities, 4 patients were assessed with liver biopsy
and 2 patients with Fibrotest-Actitest. 2 patients were treated for HCV at hospital. In 2003 and 2004, 224 patients were assessed
with Fibrotest-Actitest on site. Of these, 85 were treated for HCV. SVR was achieved in 43%. We conclude that the combination of
an onsite multidisciplinary team with the use of a noninvasive assessment method led to improved management of HCV infection
in drug users’ primary care facility.
1.Introduction
Hepatitis C is a major issue with intravenous drugs users
(IVDUs), where the prevalence of HCV is 50% to 80% [1, 2].
In addition, the prevalence of HCV infection remains high
(40% to 60%) despite harm reduction programs targeted to
recent IVDU [1]. It has been estimated that approximately
5000 new HCV cases occur per year in France of which
70% are related to drug use. The incidence of HCV in
IVDU is 10/100 persons, years versus 0.65/100.000 persons,
years in blood donors [1]. IVDUs constitute the principal
transmission reservoir for HCV. HCV infected individuals
are at risk of developing cirrhosis, end stage liver disease, and
l i v e rc a n c e r[ 3]. Nearly 50% of IVDU are infected with more
easily treatable HCV genotypes 3 or 2 [4].
IVDUsareevaluatedlessfrequentlybymedicalpersonnel
and treated less than other patients despite high willingness
to receive therapy [5]. In the United States, Canada, and
Australia, only 1%–6% of current and former IVDUs have
received HCV treatment [6–9]. The reasons for exclusion
fromtreatmentarenotbasedonevidencefromtheliterature.
Physicians fear psychiatric side eﬀects, bad adherence to
HCVtreatment,andreinfection[10].Thehighprobabilityof
residualdrugabuseoralcoholconsumptionbythesepatients
often is invoked to exclude them from treatment. Despite
those considerations, several successful HCV treatment
studies involving illicit drug users have been published over
the past years [11–26].
Wetestedthehypothesisthatevaluationandtreatmentof
HCV infected IVDU could be possible after implementation
of relevant personnel and tools in a primary care facility.
In a drug users’ addiction centre with a very low HCV
treatment uptake, we conducted an observational study of
HCV standard of care management after implementation
of an onsite multidisciplinary team and noninvasive ﬁbrosis
assessment.2 Gastroenterology Research and Practice
2. Methods
2.1. Patients. The cohort comprised patients attending the
centre between January 2002 and December 2004. The
centre oﬀered addiction services such as buprenorphine
or methadone therapy, needle exchange, counselling, and
prevention. Other routine services included general primary
care, nursing, and social support. Among 586 patients seen
in the centre at that time, 417 (70%) and tested HCV
positive. Of these, 337 were tested HCV RNA positive by
PCR.
2.2. Methods. In 2002, HCV patients were referred to
hospital. Beginning in 2003, the new strategy, including an
on-site multidisciplinary team and non-invasive assessment
was implemented. Patients were no more referred to hospital
for HCV. The onsite multidisciplinary team was composed
of ﬁve general practitioners qualiﬁed in addictive medicine,
a hepatologist on loan from a hospital, psychiatrists, two
nurses, a health counsellor, and a secretary. The general
practitioners, who provided a permanent presence in the
center, served the pivotal role of building a quality long-
term relationship with the patients by treating addiction
and Hepatitis C simultaneously. The team beneﬁted from
four hours of training per month aimed at managing the
HCV infection. The hepatologist’s mission was to motivate,
trainees and coach the general practitioners. The interaction
between the hepatologist and the general practitioners was
facilitated through regular meetings where each patient’s
ﬁle was reviewed, discussed with the entire team, and was
used as a means of training. The indications for treatment
were decided during these meetings. In addition to these
meetings, the hepatologist was easily accessible by phone to
answer the team’s questions and to solve problems within
his realm of competence. When necessary, the psychiatrists
completed an initial evaluation and ensured the follow-up,
in some cases very closely. The nurses’ role was to motivate
patients, provide them with therapeutic education, initiate
the treatment, provide ongoing access for patients’ weekly
injections of Pegylated interferon, when needed, as well as
to monitor patients’ adherence to the treatment. The nurses
providedpermanenceandwereimmediatelyavailableduring
the center’s working hours. The health counselor provided
social health service, informing and educating patients and
spending a considerable amount of time discussing and
listening to the patients’ needs.
Thepatient’sclinicalandpsychiatricevaluationwascom-
pleted at the center. Blood tests were performed in a central-
ized manner in the same laboratory.
According to oﬃcial recommendations, HCV treatment
was indicated in patients with a ﬁbrosis score ≥F2 given their
motivation and psychiatric and socioprofessional situations,
whicharoseastheresultofapreviouscourseofconsultations
with the general practitioner during an average of six
months. Patients were not referred to hospitals.
The two periods 2002 and 2003-2004 were compared in
terms of disease evaluation and initiation of treatment. The
two groups of patients were also compared in terms of age,
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Figure 1: SVR in intention to treat analysis.
2.3. Statistical Methods. The χ2 test was used to analyse the
qualitative variables and variance analysis was used for the
quantitative variables. The threshold of signiﬁcance retained
w a s5 % .T h ec a l c u l a t i o n sw e r ec a r r i e do u tw i t hN C S S
software.
3. Results
In 2002, 6 patients underwent ﬁbrosis evaluation. 4 patients
had liver biopsy and 2 patients had Fibrotest-Actitest nonin-
vasive testing in hospital. 2 patients were treated for HCV in
hospital settings. Between January 2003 and December 2004,
224 patients (group 1) underwent complete evaluation in the
centreincludingFibrotest-Actitest,while113patients(group
2) did not. Among the patients of group 2, only four patients
out of 113 (3.5%) had been already evaluated by liver biopsy
at hospital and only two patients (2%) had been treated
in 2002. Amongst group 1, 85 patients (38%) were treated
onsiteforHCVinthesameperiod.Comparisonoftreatment
uptake between the 2002 and 2003-2004 periods was highly
signiﬁcant in favour of the latest (38% versus 2% P<
.001). Comparison of clinical and biological characteristics
of groups 1 and 2 is given in table 1. In group 2, there was a
lower rate of opiate substitution (55% versus 76% P<. 001)
and a higher rate of drug abuse (61% versus 17% P<. 001).
In group 1, 85 patients (38%) were treated between January
2003 and September 2004. Among the patients of group 1,
the average index of ﬁbrosis was 0.46 ± 0.26 (F1-F2), the
average index of activity was 0.46 ± 0.25 (A1-A2). Eighty-
one patients (36%) had minimal ﬁbrosis F0, F0-F1, and F1;
66 patients (30%) had moderate ﬁbrosis F1-F2 and F2; 77
patients (34%) had severe ﬁbrosis F3, F3-F4, and F4. The
averageageoftreatedpatientswas42 ±5.2years.Theaverage
index of ﬁbrosis was 0.62 ± 0.19 (F3) among treated patients
versus 0.39 ± 0.26 (F1-F2) among untreated patients (P<
.001). Among the treated patients, 20 (23%) used drugs,
37 (44%) had alcohol consumption higher than 50 grams
per day, and 62 (73%) had opiate substitution treatment.
In intention to treat 37 patients (43%) had a sustained
response, 10 among 38 genotype 1 (26%) and 25 among 42
genotype 2 and 3 (60%) patients (Figure 1). Fifteen patientsGastroenterology Research and Practice 3
Table 1: Comparison of clinical and biological characteristics between groups 1 and 2.
Group 1 N = 224 Group 2 N = 113
Mean age 40 37
Genotype 2 or 3 46% 49%
Drug use 38 (17%) 69 (61%) P<. 001
Alcohol use 83 (37%) 45 (40%) NS
Substitution 169 (76%) 62 (55%) P<. 001
HCV treatment 85 (38%) (2003-2004) 2 (2%) (2002) P<. 001
(17%)stoppedthetreatmentprematurely:fourpatientswere
lost to follow-up, one patient had a cardiac complication,
one patient had hyperthyroidism, ﬁve patients suﬀered from
adverse psychiatric events in the form of depression and/or
severe alcoholism, and four patients stopped treatment after
the ﬁrst injection because of the anxiety generated by a
pseudo syndrome of opiate withdrawal.
4. Discussion
While HCV appears to be a major prevalent issue in IVDU
patients, it is clearly undertreated in this population. On
the other hand, IV drug use is the ﬁrst risk factor of HCV
transmission and risk reduction policies did not reduce
dramatically HCV transmission and prevalence in this
population. HCV is associated with a risk of morbidity and
mortality. Combination treatment consisting of pegylated
interferon and ribavirin has been shown to be highly
eﬀective, achieving viral clearance rates between 55% and
85% depending on genotype [27, 28].
DecreaseduptakeoftreatmentamongIVDUsisprobably
attributedtobothhealthcareproviderandpatient-associated
factors. Treatment for HCV infection among IVDUs may
be withheld by physicians to perceived “diﬃcult” patients
based on concerns of adherence and treatment sideeﬀects
[10]. Current hospital protocols seem of limited utility
for treatment of HCV in IVDUs [10]. On the patient’s
side psychiatric comorbidities and poor social support are
common among IVDUs and HCV treatment may not be a
high priority for them. Therefore,new strategies are required
to treat HCV in this population.
It has been demonstrated that when speciﬁc programs
are developed, IVDU can be successfully treated for HCV.
Response rates following HCV treatment in IVDU [11–26]
are close to the response rates in large clinical trials [27, 28].
The aim of this study was to observe the contribution
of a diﬀerent healthcare organisation on HCV standard of
care evaluation and treatment. Within a primary healthcare
setting for IVDU, HCV-positive patients were able to beneﬁt
from a strategy that consisted of an onsite total care
concept provided by a multidisciplinary team including a
referred delegated hepatologist and HCV evaluation using
Fibrotest-Actitest a biomarker noninvasive method. We did
not use combination with Fibroscan because it was not
easily accessible as a routine assessment method at that time.
Among a group of 417 HCV-positive patients of which 337
subjects were viremic, 224 were evaluated for ﬁbrosis and
85 of them were treated after two years. During the year
which preceded the realization of this “all under one roof
total care concept”, only 6 liver evaluations and 2 treatments
were carried out at hospitals. Patients undergoing complete
evaluation had a signiﬁcant higher rate of opiate substitution
treatment. Substitution appeared to be a major precondition
for access to care in this population.
Treatmentindicationsfollowedoﬃcialguidelinesrecom-
mending HCV treatment in patients with ﬁbrosis ≥F2. The
rate of sustained viral response was 43% in intention to treat
analysis. This result is reasonable if we consider that the
treated patients had an average F3 ﬁbrosis index and that
50%hadgenotype1infection.Noseriousadversepsychiatric
event was observed.
HCV screening, assessment, and treatment seem feasible
and eﬃcient in IVDU. It requires a speciﬁc adaptation of the
healthcare system to this particular population. In our study,
it appears more eﬃcient to propose onsite multidisciplinary
care in an IVDU primary care centre rather than referral to
hospital.
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